Core Viewpoint - Bristol Myers Squibb and Johnson & Johnson have decided to halt a late-stage trial of their experimental blood clot drug for heart attack patients following an independent review that raised concerns about the study's findings [1] Group 1 - The independent review indicated that the study did not meet its primary endpoint, leading to the decision to stop the trial [1] - The drug was being tested for its efficacy in treating heart attack patients, but the results were not favorable enough to continue [1] - This decision may impact the companies' future product pipeline and market strategies in the cardiovascular space [1]